Glenmark Therapeutics Inc USA announced on Monday the launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), a generic version of Pataday Once Daily Relief.

The antihistamine eye drops are intended for temporarily relieving itchy eyes due to pollen, ragweed, grass, animal hair and dander.

According to data and analytics company Nielsen, in syndicated data for the 52 weeks ending 17 May 2025 the Pataday Once Daily Relief (OTC) market achieved annual sales of approximately USD50.0m.

Commenting on the launch, Marc Kikuchi, president & business head, North America said: "We are excited to announce the launch of Olopatadine Ophthalmic Solution USP, 0.2%, addressing the growing demand for a new supplier in this category. This addition highlights our commitment to meeting market needs and providing high-quality over-the-counter solutions for our customers."